Clinical Significance of Phenotyping and Karyotyping of Circulating Tumor Cells in Patients with Advanced Gastric Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2014 Jul 16

PMID 25026283

Citations 54

Authors

Yilin Li

Xiaotian Zhang

Sai Ge

Jing Gao

Jifang Gong

Ming Lu

Qiyue Zhang

Yanshuo Cao

Daisy Dandan Wang

Peter Ping Lin

Lin Shen

Affiliations

Soon will be listed here.

Abstract

Background: Karyotyping and phenotyping of circulating tumor cells (CTCs) in therapeutic cancer patients is of particular clinical significance in terms of both identifying chemo-resistant CTC subtypes and understanding CTC evolution.

Methods: The integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform was applied to detect and characterize CTCs in patients with advanced gastric cancer (AGC). Status of human epidermal growth factor receptor 2 (HER2) expressing and aneuploidy of chromosome 8 in CTCs enriched from the patients was examined by SET-iFISH following clinical chemotherapy or HER2-targeted therapy. CellSearch system was applied as a reference control.

Results: Phenotyping of CTCs in HER2 positive AGC patients demonstrated that HER2⁺ CTCs could be effectively eliminated in response to HER2-targeted therapy. Karytotyping of CTCs indicated that distinct CTCs with different ploidies of chromosomes 8 in AGC patients correlated to either sensitivity or resistance of paclitaxel or cisplatin-based chemotherapy. Examination of the copy number of chromosome 8 in CTCs provides a potential approach for predicting chemotherapeutic efficacy and monitoring chemo-resistance.

Conclusions: Phenotyping and karyotyping of the enriched CTCs upon ploidy of chromosome 8 or HER2 expression is of clinical potential for monitoring chemo-resistance and evaluating therapeutic efficacy for AGC patients.

Citing Articles

Circulating tumor cells are a good predictor of tumor recurrence in clinical patients with gastric cancer.

Li W, Zhang X, Yang Y, Lin J, Zhou K, Sun R Sci Rep. 2024; 14(1):12758.

PMID: 38830909 PMC: 11148116. DOI: 10.1038/s41598-024-63305-3.

Detection of chromosomal instability using ultrasensitive chromosomal aneuploidy detection in the diagnosis of precancerous lesions of gastric cancer.

Qian S, Xie F, Zhao H, Jiang T, Sang Y, Ye W Front Genet. 2024; 15:1359231.

PMID: 38660675 PMC: 11040259. DOI: 10.3389/fgene.2024.1359231.

Investigating the role of circulating tumor cells in gastric cancer: a comprehensive systematic review and meta-analysis.

Eskandarion M, Eskandarieh S, Tutunchi S, Shakoori Farahani A, Shirkoohi R Clin Exp Med. 2024; 24(1):59.

PMID: 38554188 PMC: 10981629. DOI: 10.1007/s10238-024-01310-6.

Applications of single‑cell omics and spatial transcriptomics technologies in gastric cancer (Review).

Ren L, Huang D, Liu H, Ning L, Cai P, Yu X Oncol Lett. 2024; 27(4):152.

PMID: 38406595 PMC: 10885005. DOI: 10.3892/ol.2024.14285.

Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer.

Ma G, Wang J, Fu J, Chen R, Liang M, Li M Breast Cancer Res Treat. 2023; 201(1):27-41.

PMID: 37311933 DOI: 10.1007/s10549-023-06942-y.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Barok M, Balazs M, Nagy P, Rakosy Z, Treszl A, Toth E . Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett. 2007; 260(1-2):198-208. DOI: 10.1016/j.canlet.2007.10.043. View

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

Hartgrink H, Jansen E, van Grieken N, van de Velde C . Gastric cancer. Lancet. 2009; 374(9688):477-90. PMC: 4613761. DOI: 10.1016/S0140-6736(09)60617-6. View

Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L . Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol. 2008; 4(1):30-6. DOI: 10.1097/JTO.0b013e3181914125. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Swennenhuis J, Tibbe A, Levink R, Sipkema R, Terstappen L . Characterization of circulating tumor cells by fluorescence in situ hybridization. Cytometry A. 2009; 75(6):520-7. DOI: 10.1002/cyto.a.20718. View

Wenqi D, Li W, Shanshan C, Bei C, Yafei Z, Feihu B . EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol. 2009; 135(9):1277-85. DOI: 10.1007/s00432-009-0569-5. View

Shen L, Shan Y, Hu H, Price T, Sirohi B, Yeh K . Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013; 14(12):e535-47. DOI: 10.1016/S1470-2045(13)70436-4. View

10.

Lee A, Endesfelder D, Rowan A, Walther A, Birkbak N, Futreal P . Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011; 71(5):1858-70. PMC: 3059493. DOI: 10.1158/0008-5472.CAN-10-3604. View

11.

Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D . Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339(6119):580-4. PMC: 3760262. DOI: 10.1126/science.1228522. View

12.

Mayer J, Pham T, Wong K, Scoggin J, Sales E, Clarin T . FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform. Cancer Genet. 2011; 204(11):589-95. DOI: 10.1016/j.cancergen.2011.10.011. View

13.

Ran R, Li L, Wang M, Wang S, Zheng Z, Lin P . Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood. Anal Bioanal Chem. 2013; 405(23):7377-82. DOI: 10.1007/s00216-013-7156-y. View

14.

Alix-Panabieres C, Pantel K . Circulating tumor cells: liquid biopsy of cancer. Clin Chem. 2012; 59(1):110-8. DOI: 10.1373/clinchem.2012.194258. View

15.

Hayes D, Walker T, Singh B, Vitetta E, UHR J, Gross S . Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol. 2002; 21(5):1111-7. DOI: 10.3892/ijo.21.5.1111. View

16.

Deneve E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daures J . Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem. 2013; 59(9):1384-92. DOI: 10.1373/clinchem.2013.202846. View

17.

Ren C, He P, Zhang J, Zheng Z, Qiao Y, Zhao X . Malignant characteristics of circulating tumor cells and corresponding primary tumor in a patient with esophageal squamous cell carcinoma before and after surgery. Cancer Biol Ther. 2011; 11(7):633-8. DOI: 10.4161/cbt.11.7.14950. View

18.

Iwatsuki M, Toyoshima K, Watanabe M, Hayashi N, Ishimoto T, Eto K . Frequency of HER2 expression of circulating tumour cells in patients with metastatic or recurrent gastrointestinal cancer. Br J Cancer. 2013; 109(11):2829-32. PMC: 3844922. DOI: 10.1038/bjc.2013.680. View

19.

Duesberg P, Li R, Sachs R, Fabarius A, Upender M, Hehlmann R . Cancer drug resistance: the central role of the karyotype. Drug Resist Updat. 2007; 10(1-2):51-8. DOI: 10.1016/j.drup.2007.02.003. View

20.

Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D . Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res. 2002; 8(7):2073-84. View